Trial Profile

A Phase I, Dose Escalation and Dose Expansion, Safety and Tolerability Study of onCARlytics (CF33-CD19), Administered Intravenously or Intratumorally in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 14 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Blinatumomab (Primary) ; Hydroxycarbamide (Primary) ; OnCARlytics (Primary) ; OnCARlytics (Primary)
Indications Advanced breast cancer; Cholangiocarcinoma; Malignant melanoma; Ovarian cancer; Solid tumours
Focus Adverse reactions
Acronyms OASIS
Sponsors Imugene

09 Apr 2025 Trial arms increased from 4 to 6. Drug Hydroxyurea added newly to the interventional arms.
09 Apr 2025 Planned number of patients changed from 33 to 50.
22 Oct 2024 Planned number of patients changed from 52 to 33.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com